TM6SF2 and hepatocellular carcinoma: The VAFs of PNPLA3 (81.3%, p <0.05), MBOAT7 (41.9%), and TM6SF2 (5.6%) were higher in patients with HCC, whereas the VAF of HSD17B13 (5.9%, p <0.05) was lower in the HCC group compared with the gnomAD database.